Graves’ disease is an autoimmune disorder that stimulates the thyroid gland to release excessive thyroid hormone, leading to hyperthyroidism. It is termed as Basedow’s disease in continental Europe and Graves’ disease in the U.S.

In this disease, body’s immune system produces antibodies that help the thyroid gland to grow which in turn synthesizes abnormal levels of thyroid hormones causing hyperthyroidism. Graves’ disease is the most predominant cause of hyperthyroidism in the U.S. A study conducted in Minnesota estimated the incidence of the disease at 30 cases per 1 million persons. Approximately 1 in every 500 women has maternal thyrotoxicosis. According to the Wickham study in England, Graves’ disease accounted for 0.5 cases per 1000 persons, with higher rate of incidence in people aged between 40 and 60. After Hashimoto thyroiditis, Graves’ disease is the most prevalent autoimmune thyroid disorder in the U.S. Through a study conducted by PREGO (presentation of Graves orbitopathy), the annual incidence of Graves’ orbitopathy in Europe was 10-30/10,000 human subjects but over a period of time, the severity and incidence of Graves’ disease in Europe has been observed to decrease to 2.10/10,000/year.

As with most autoimmune diseases, Graves’ disease is also more likely to affect women than men. Hyperthyroidism due to Graves’ disease has a female-to-male ratio of 7-8:1. Typically, it is a disease of young women, but it can occur in persons of any age. The prevalence rate for Graves’ disease is similar in both Asians and Caucasians, but is lower in the African population.

Treatment of Graves’ disease involves reduction of abnormal thyroid hormone levels and relieving the associated discomfort. The three standard treatment options are the use of anti-thyroid drugs, radioactive iodine ablation, and thyroidectomy. All three treatments inhibit overproduction of thyroid hormone. The least invasive and typical first-line therapy for Graves’ disease is the use of anti-thyroid drugs, which slows down thyroid activity and inhibits production of thyroid hormone. Propylthiouracil (PTU) and methimazole (MMI) are inexpensive, devoid of side effects, and are the most commonly used treatment option for this disease.

Iodine-131 is used in radioactive iodine ablation (RIA) to destroy entire or part of the thyroid gland, resulting in prevention of overproduction of thyroid hormone. Removal of the thyroid gland through surgery called subtotal thyroidectomy is one of the most invasive treatment options. Irrespective of the treatment method, patients have to follow long term treatment regimens to ward off the chances of hyperthyroidism or occurrence of hypothyroidism. Thyroid hormone replacement therapy along the length of the patient’s life is necessary. This presents large opportunities for new players in the market.

Rise in number of patients with thyroid disorders, favorable reimbursement policies for treatment, and increase in awareness about the complications associated with thyroid disorders are the major drivers of the Graves’ disease market. Increasing iodine disorder and thyroid tumors screening is one of the leading factors fueling the growth of the market.

Based on the product type Graves’ disease drugs could be classified into Anti-thyroid drugs, Iodine & Iodides, Radioactive Iodine, Ionic Inhibitors. Anti-thyroid drug is further segmented into Beta-adrenergic blockers, thiomides and corticosteroids

The Graves’ disease market is anticipated to witness moderate growth. In terms of region, the Graves’ disease drug market has been segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is anticipated to be the major market for thyroid related disorders followed by Europe. Asia Pacific is likely to be the fastest growing market for thyroid related disorders drugs due to increased health care investments, rise in awareness about hyperthyroidism, and various treatment options available.

Key players in the Graves’ disease market are Abbott Laboratories, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., RLC LABS, AbbVie, Inc., Mylan N.V., and Allergan, plc., and others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Graves Disease Market

Pre Book